At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia.
Questions
1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05)
2. Following discontinuation of TKIs in patients with CML, when are relapses most likely to occur? (1:20)
3. What are the current recommendations for monitoring patients following TKI discontinuation? (1:40)
4. What factors predict which patients are likely to relapse? (2:39)
5. Could you tell us a little about your study, its findings and their implications? (3:24)
Massimo Breccia has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
